3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
14
Nivolumab
13
Sunitinib
12
Axitinib
9
cabozantinib
8
belzutifan
8
Ipilimumab
7
Everolimus
5
atezolizumab
4
Sorafenib
4
temsirolimus
3
perifosine
3
motexafin gadolinium
3
Drug Therapy
3
spartalizumab
2
palbociclib
2
liposomal doxorubicin
2
lenvatinib
2
entinostat
2
ciforadenant
2
belinostat
2
avelumab
2
Paclitaxel
2
Immunotherapy
2
G250 monoclonal antibody
2
Fluorouracil
2
Docetaxel
2
Dexamethasone
2
Cetuximab
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Kidney Neoplasms
×
Blood Component Removal
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled